Evidence map›Paper›PMID 31995801›Full record

ArticleBlood purification2020

In vitro Evaluation of Linezolid and Doripenem Clearance with Different Hemofilters.

Toshihisa Hiraiwa, Kazuhiro Moriyama, Kana Matsumoto, Yasuyo Shimomura, Yu Kato, Chizuru Yamashita, Yoshitaka Hara, Takahiro Kawaji, Yasuyoshi Kurimoto, Tomoyuki Nakamura and 5 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Blood purification, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Toshihisa HiraiwaDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Kazuhiro MoriyamaLaboratory for Immune Response and Regulatory Medicine, Fujita Health University School of Medicine, Toyoake, Japan, morimori@fujita-hu.ac.jp.
Kana MatsumotoDepartment of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan.
Yasuyo ShimomuraDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Yu KatoDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Chizuru YamashitaDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Yoshitaka HaraDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Takahiro KawajiDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Yasuyoshi KurimotoDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Tomoyuki NakamuraDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Naohide KuriyamaDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Junpei ShibataDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Hidefumi KomuraDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Kunihiko MoritaDepartment of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan.
Osamu NishidaDepartment of Anesthesiology and Clinical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Fujita Health University · JPDoshisha Women's College of Liberal Arts · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRenal replacement therapy (RRT) is widely used in the treatment of septic acute kidney injury. However, little is known about how the adsorption properties of hemofilters used in RRT affect antibiotic concentration. Because a cytokine-adsorption membrane is frequently used in RRT, it is important to determine the antibiotic adsorption capacity of this membrane.

objectiveThe present study aimed to investigate the antibiotic adsorption capacity of different hemofilter membranes by in vitro experiments using 2 antibacterial agents (linezolid and doripenem).

methodsWe performed experimental hemofiltration in vitro using polyacrylonitrile (AN69ST), polymethylmethacrylate (PMMA), and polysulfone (PS) hemofilters for 1,440 min. The test solution was a 1,000-mL substitution fluid containing 30 µg/mL linezolid and 120 µg/mL doripenem. We measured drug concentrations at the inlet, outlet, and filtrate ports of the hemofilters for 1,440 min and calculated the sieving coefficient (SC) and adsorption rate (Ra) of the drugs onto the hemofilters.

resultsThe amount of linezolid adsorbed onto AN69ST, PMMA, and PS membranes was decreased relative to that in the control group at 15 min (p < 0.05). However, no SC for linezolid was obtained thereafter. The Ra of linezolid onto AN69ST, PMMA, and PS membranes was higher than that in the control group (p < 0.05). In contrast, no significant differences were observed in the concentrations and Ra values of doripenem adsorbed onto AN69ST, PMMA, and PS membranes compared with those in the control group.

conclusionsDoripenem was not adsorbed onto PMMA, PS, and AN69ST membranes. Linezolid was adsorbed onto PMMA, PS, and AN69ST membranes, but only temporarily, and this did not affect drug bioavailability.

Indexed as

Membranes, ArtificialAcrylic ResinsAdsorptionAnti-Bacterial AgentsDoripenemHemofiltrationHumansLinezolidPolymersPolymethyl MethacrylateSulfonesAcrylic ResinsAnti-Bacterial AgentsDoripenemLinezolidMembranes, ArtificialpolyacrylonitrilePolymersPolymethyl Methacrylatepolysulfone P 1700SulfonesAdsorptionDoripenemExperimental modelHemofilterLinezolid

Identifiers

PMID31995801
PMCPMC7212696
OpenAlexW3004104877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.